Rare disease products had long been at the margin of payer's concerns because of their limited use, but as the number of products, and some of their prices, has ballooned, orphan drugs have begun to figure prominently in the budgets of some insurers. Now rare disease patients and advocates may find themselves in the epicenter of the drug pricing debate as they fan out across Capitol Hill to lobby for increased treatments during Rare Disease Week.
The prelude to the lobbying blitz was the Feb. 26 Rare Disease Legislative Advocates (RDLA) Legislative Conference, where congressional staffers...







